NCT01931150View on ClinicalTrials.gov

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

PHASE3CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Cetuximab-induced Papulopustular (Acneiform) Rash Who HaveMetastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Topical Dapsone 5% Gel

OTHER

Moisturizer

The moisturizer for the study will be Vanicream™ Lite Lotion.

DRUG

oral antibiotics

Trial Locations (1)

10021

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01931150 - Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT | Biotech Hunter | Biotech Hunter